AI
| Followers | 842 |
| Posts | 122793 |
| Boards Moderated | 10 |
| Alias Born | 09/05/2002 |
Thursday, December 04, 2008 1:54:08 AM
Lumilash update (including before/after photos):
The FDA briefing docs are out for Friday’s panel meeting, and they appear to be good for AGN.
http://www.reuters.com/article/marketsNews/idINN0332186720081203
Before and After Photos of Lumilash
from Allergan’s clinical trial. The p-value
was <0.0000000000000000000001.
Lumilash is going to be one of the biggest-selling cosmeceuticals of all time, IMO. It’s the kind of product that marketing people dream about: blowout efficacy, minimal side effects, trivially easy administration, and the need to continue use forever to maintain results.
AGN estimates that the product will do $500M in peak annual sales, but I think they are deliberately low-balling.
The FDA briefing docs are out for Friday’s panel meeting, and they appear to be good for AGN.
http://www.reuters.com/article/marketsNews/idINN0332186720081203
Before and After Photos of Lumilash
from Allergan’s clinical trial. The p-value
was <0.0000000000000000000001.
Lumilash is going to be one of the biggest-selling cosmeceuticals of all time, IMO. It’s the kind of product that marketing people dream about: blowout efficacy, minimal side effects, trivially easy administration, and the need to continue use forever to maintain results.
AGN estimates that the product will do $500M in peak annual sales, but I think they are deliberately low-balling.
Trade Smarter with Thousands
Leverage decades of market experience shared openly.
